|
Alfentanil
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Amiodarone
|
Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
|
|
Atorvastatin
|
Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
|
|
Buprenorphine
|
Opioids like buprenorphine may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Consider therapy modification.
|
|
Butorphanol
|
Opioid analgesics such as butorphanol may enhance the adverse/toxic effect of alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. According to alvimopan prescribing information, alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Monitor for increased alvimopan adverse effects in patients using opioids prior to alvimopan.
|
|
Clarithromycin
|
Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
|
|
Clotrimazole
|
Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
|
|
Codeine
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Dextromoramide
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Dezocine
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Difenoxin
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Dihydrocodeine
|
Opioids may enhance Alvimopan toxicity, especially when opiate use for more than 7 days is in place prior to alvimopan initiation. Alvimopan is contraindicated for use if patients have been dosed with opioids for more than 7 consecutive days.
|
|
Diphenoxylate
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Dipipanone
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Fentanyl
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Heroin
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Hydrocodone
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Hydromorphone
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Ivacaftor
|
Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
|
|
Levomethadyl Acetate
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Levorphanol
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Meperidine
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Methadone
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Morphine
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Nalbuphine
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Oxycodone
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Oxymorphone
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Papaverine
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Pentazocine
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Propoxyphene
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Quinidine
|
Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
|
|
Sufentanil
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Tapentadol
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|
|
Tramadol
|
Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
|